DD CIRM Grant

On August 18, 2024, CIRM awarded the Company up to $5.8 million under a CLIN2 grant award to support the clinical development of its AAV-based genetic medicines, RP-A501 for the treatment of DD. Proceeds from the grant would help fund clinical trial costs as well as manufactured drug product for Phase 1/2 patients. During the three and six months ended June 30, 2026, the Company did not receive any grants. During the three and six months ended June 30, 2025, the Company received grants of $0 and $2.7 million, respectively, which were recorded as a reduction of R&D expenses. Through June 30, 2026, the Company has received total RP-A501 grants of $5.0 million from CIRM. No additional milestones were met during the six months ended June 30, 2026.